Clinical Trials
4
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)A Phase I Study of GFH312 in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: GFH312 200 mgDrug: GFH312 120mgOther: PlaceboDrug: GFH312 100 mg
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05991362
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
Phase 2
Withdrawn
- Conditions
- Intermittent ClaudicationPeripheral Artery Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
- Registration Number
- NCT05618691
- Locations
- 🇺🇸
Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
- Registration Number
- NCT05165849
A Study of GFH018 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05051241
- Locations
- 🇨🇳
Shanghai East hospital, Shanghai, China
News
No news found